An observational study in Sensory Neuropathy, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Not yet recruiting at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Sensory neuronopathies (SNNs) are rare disorders characterized by damage to sensory neurons in the dorsal root ganglia. They may have dysimmune, paraneoplastic, toxic, or genetic causes. Alcohol-related nutritional sensory neuronopathy has recently been described and may present acutely or subacutely with pain, mimicking dysimmune or paraneoplastic disease. Distinguishing these causes early may help guide appropriate management. This international, multicentre, retrospective observational cohort study will describe the initial and follow-up clinical and electrophysiological phenotype of acute/subacute alcohol-related nutritional SNN and compare it with dysimmune and paraneoplastic SNN. Data will be abstracted from existing medical records. The protocol anticipates approximately 75 participants with alcohol-related nutritional SNN, 50 with dysimmune SNN, and 20 with paraneoplastic SNN. No additional procedure is performed for research purposes and no direct benefit is expected for participants.
Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients monitored in a neurology department for their sensory neuropathies
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria :
Adults with probable acute/subacute SNN attributed to chronic alcohol misuse (\>100 g ethanol/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded using the minimum work-up specified in the protocol.
Adults with probable acute/subacute SNN attributed to Sjögren's syndrome, lupus, primary biliary cholangitis, or associated with anti-FGFR3 or anti-AGO antibodies.
Adults with probable acute/subacute SNN associated with anti-Hu or anti-CV2/CRMP5 antibodies.
Demographic and disease onset characteristics
Description of demographic characteristics and disease onset, including age at onset (years), mode of onset, and initial symptoms. Each variable will be reported individually, as available in the medical records.
Time frame: from july 2006 to april 2027
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Saint Etienne →